- Home
- DNTH vs XPEL Comparison
DNTH vs XPEL Comparison
Compare DNTH & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- XPEL
- Stock Information
- Founded
- DNTH 2015
- XPEL 1999
- Country
- DNTH United States
- XPEL United States
- Employees
- DNTH N/A
- XPEL N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- XPEL Industrial Specialties
- Sector
- DNTH Health Care
- XPEL Industrials
- Exchange
- DNTH Nasdaq
- XPEL Nasdaq
- Market Cap
- DNTH 1.0B
- XPEL 984.3M
- IPO Year
- DNTH N/A
- XPEL N/A
- Fundamental
- Price
- DNTH $37.04
- XPEL $34.32
- Analyst Decision
- DNTH Strong Buy
- XPEL
- Analyst Count
- DNTH 9
- XPEL 0
- Target Price
- DNTH $61.57
- XPEL N/A
- AVG Volume (30 Days)
- DNTH 969.3K
- XPEL 157.4K
- Earning Date
- DNTH 11-06-2025
- XPEL 11-06-2025
- Dividend Yield
- DNTH N/A
- XPEL N/A
- EPS Growth
- DNTH N/A
- XPEL 2.75
- EPS
- DNTH N/A
- XPEL 1.76
- Revenue
- DNTH $4,854,000.00
- XPEL $448,897,000.00
- Revenue This Year
- DNTH N/A
- XPEL $12.54
- Revenue Next Year
- DNTH N/A
- XPEL $10.52
- P/E Ratio
- DNTH N/A
- XPEL $19.53
- Revenue Growth
- DNTH 17.87
- XPEL 9.96
- 52 Week Low
- DNTH $13.37
- XPEL $24.25
- 52 Week High
- DNTH $38.59
- XPEL $47.23
- Technical
- Relative Strength Index (RSI)
- DNTH 82.86
- XPEL 41.63
- Support Level
- DNTH $36.00
- XPEL $35.69
- Resistance Level
- DNTH $24.81
- XPEL $37.76
- Average True Range (ATR)
- DNTH 2.70
- XPEL 1.52
- MACD
- DNTH 1.31
- XPEL -0.35
- Stochastic Oscillator
- DNTH 90.18
- XPEL 1.81
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.